PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Clinical Pharmacology, Ono Pharmaceutical Co., Ltd., Osaka, Japan.\', \'Department of Bioscience and Bioinformatics, Kyushu Institute of Technology, Fukuoka, Japan.\', \'Pharmacokinetic Research, Ono Pharmaceutical Co., Ltd., Ibaraki, Japan.\', \'SOUSEIKAI Hakata Clinic, Fukuoka, Japan.\', \'Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, Oita, Japan.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1111/cts.13052
?:doi
?:hasPublicationType
?:journal
  • Clinical and translational science
is ?:pmid of
?:pmid
?:pmid
  • 33982445
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.669
?:rankingScore_hIndex
  • 31
is ?:relation_isRelatedTo_publication of
?:title
  • A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33982445>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33982445>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all